Skip to main content
Clinical Trials/NCT04869904
NCT04869904UnknownNot Applicable

Analysis of the Periodontal Microbiota in Elderly Subjects With and Without Alzheimer's Disease: a Case Control Study

Centre Hospitalier Universitaire de Nice1 site in 1 country80 target enrollmentStarted: June 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
80
Locations
1
Primary Endpoint
Quantification of periodontal bacterial and viral species from dental plaque samples

Study Overview

Brief Summary

The neurological disorders that accompany aging represent a major public health problem. The management of these diseases is a major medical and social priority. This project is based on the assumption that the oral cavity represents a privileged observation space to address these issues. The mouth is a site of easy access for painless sampling; there is therefore a major interest in identifying early oral infectious markers of the development or evolution of senile dementia. In addition to the interest of an early oral diagnosis, the mapping of the oral microbial flora in the demented elderly would allow a better understanding, prevention or even control of the evolution of neurodegenerative diseases. The final objective of our approach is to characterize the oral pathogens, or more probably the group of oral pathogens, which are significantly associated with Alzheimer's disease.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
70 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age greater than or equal to 70 years old
  • Patient (or trusted person) having read and understood the study information note and signed the informed consent form
  • Membership in a social security scheme
  • For cases : Diagnosis of possible or probable Alzheimer's disease according to the DSM-V

Exclusion Criteria

  • Presence of a neurodegenerative pathology (excluding Alzheimer's disease for cases)
  • Presence of a neurocognitive disorder (excluding Alzheimer's disease for the cases)
  • Patient with or having had any kind of cancer, including oral or aerodigestive tract
  • Patients with or having had autoimmune diseases (HIV, hepatitis)
  • Patients with inflammatory diseases (such as rheumatoid arthritis (RA) or Gougerot-Sjogren's syndrome (GSJ))
  • Patients with severe haemopathy
  • Patients with severe acute or chronic cardiovascular, renal, hepatic, gastrointestinal, allergic, endocrine, pulmonary, neuropsychiatric pathologies, judged by the investigator to be incompatible with the study, as all these pathologies may interfere with the results of the oral flora sampling
  • Patients who have undergone oral surgery in the two months prior to sampling
  • Patients treated with oral retinoids, bisphosphonates, oral anticoagulants or anticonvulsants
  • Patients who have had anti-cancer or immunosuppressive chemotherapy within the last 6 months
  • Patient who has had antibiotic or anti-inflammatory treatment in the last 4 weeks
  • A history of treatments (drugs and probiotics) taken in the month prior to sampling will be taken, as well as a record of toxic habits (tobacco, alcohol, other)

Outcomes

Primary Outcomes

Quantification of periodontal bacterial and viral species from dental plaque samples

Time Frame: 9 months

Quantification of periodontal bacterial and viral species by microfluidic multiplex PCR-Biomark HD system Microfluidigm 9 Herpes viruses = HSV-1 and 2 (or HHV-1 and -2), VZV (or HHV-3), EBV (or HHV-4), CMV (or HHV-5), HHV-6A, HHV-6B, HHV-7, HHV-8 (or Kaposi virus) 16 periodontal bacteria = Porphyromonas gingivalis, Tannerella forsythensis, Treponema denticola, Prevotella intermedia, Campylobacter rectus, Fusobacterium nucleatum, Prevotella nigrescens, Eubacterium nodatum, Peptostreptococcus micros, Prevotella melaninogenica, Aa, Actinomyces naeslundii, Eikenella corrodens, Streptococcus mitis, Streptococcus oralis, Streptococcus sanguis For each species: Less than 25 CT (Cycle Treshold): positive More than 30 CT (Cycle Treshold): negative Between 25 and 30 CT (Cycle Treshold): need to increase significance by using an additional primer CT: allows to determine the number of copies of each bacterial or viral species

Secondary Outcomes

  • Oral status mobilities(1 day)
  • Oral status presence of dentures(9 Months)
  • Oral status caries involvement(1 day)
  • Periodontal status: bleeding on probing (BOP):(9 months)
  • Oral status masticatory coefficient(9 Months)
  • Periodontal status: pocket depth (PPS)(9 months)
  • Periodontal status: clinical attachment (CAL)(9 months)
  • Periodontal status: plaque index (PI)(9 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Oral Bacterial and Viral Mapping by Dental... | Clinical Trial